Paul Mann, CEO of ASP Isotopes (Nasdaq: ASPI), joins us to break down the company's shift from isotope developer to commercial-scale critical materials supplier.ASP Isotopes uses its proprietary Aerodynamic Separation Process and Quantum Enrichment technology to produce isotopes and critical gases for semiconductors, nuclear medicine, and clean energy. The world is facing real shortages in these materials, many historically dependent on Russia and China, and ASPI is building out manufacturing capacity across three major verticals: electronics, nuclear medicine, and nuclear energy.Over the next 12 to 18 months, ASPI expects four plants, three for isotopes and one for helium, to begin commercial production, a milestone management says will start generating free cash flow. Additional facilities are planned in Iceland, the UK, and the US, along with a large-scale helium expansion in South Africa.👉 ASP Isotopes is a client of RedChip. To learn more about ASPI and to read our full disclosure, visit: https://www.redchip.com/stocks/ASPI#ASPI #ASPIsotopes #Nasdaq #SmallCapStocks #CriticalMaterials #NuclearEnergy #InvestorBrief #StockMarket #EnergyStocks #SupplyChain #CleanEnergy

Co-CEO Bob Brilon joins RedChip to discuss Bimergen Energy's (NYSE American: BESS) strategy for building, financing, and operating utility-scale and distributed battery energy storage systems across the fastest-growing power markets in the United States.Bimergen develops battery farms — tractor-trailer-sized battery systems deployed across 10 to 30 acres — with a typical project capacity of 100 MW at an approximate cost of $125 million each. The company owns 23+ development-stage BESS projects totaling approximately 2 GW of planned capacity across ERCOT, PJM, WECC, and MISO markets, acquired in April 2024 and providing roughly a four-year runway of deal flow. Bimergen's capital-efficient model relies on 100% project-level debt financing, meaning equity capital is preserved while the portfolio scales. Federal investment tax credits of up to 50% of project CapEx can be monetized immediately upon commercial operation, reducing the effective cost of a $125 million project by up to $60 million and accelerating debt paydown.With 23 projects on the books, an asset base carried at $22 million but representing an estimated $150 million in joint venture value, and a NYSE American listing supporting institutional visibility, Bimergen is transitioning from development-stage developer to emerging independent power producer.👉 Bimergen Energy is a client of RedChip. To learn more about BESS and to read our full disclosure, visit: https://www.BESSinfo.com#BESS #BimergenEnergy #BatteryStorage #EnergyStorage #GridScale #SmallCapStocks #MicroCapStocks #EnergyStocks #CleanEnergy #ERCOT #NYSE #StockInterviews #InvestorEducation #RenewableEnergy

CEO Lavell Juan Malloy II joins RedChip to discuss Brag House (Nasdaq: TBH), a media-tech platform building at the intersection of Gen Z fandom, blockchain infrastructure, and global athlete IP.Brag House is built on the belief that culture is capital. With its shareholder-approved merger with House of Doge — the official corporate arm of the Dogecoin Foundation — the company is evolving into a full-stack financial infrastructure platform targeting the $2.3 trillion global sports economy. The combined entity is designed to connect fans, athletes, and brands through blockchain payment rails, NIL tokenization, and digital ownership tools that today's fragmented sports finance infrastructure lacks.CEO Malloy breaks down the company's closed-loop revenue model, its Gen Z community advantage, key partnerships with Learfield and major university athletics programs, and why management believes the merger — approved by 98% of shareholders — marks the beginning of a much larger global expansion.👉 TBH is a client of Redchip. To learn more about TBH and to read our full disclosure, visit: https://redchip.com/stocks/tbh#TBH #BragHouse #HouseofDoge #Dogecoin #BlockchainSports #AthleteTokenization #GenZInvesting #NIL #SmallCapStocks #MicroCapStocks #FinTech #SportsTech #InvestorEducation #StockInterviews

In our investor-focused interview, James Foster, CEO of Virax Biolabs Group Ltd. (Nasdaq: VRAX), breaks down how the company is developing a potential first-in-category immune function diagnostic targeting post-acute infection syndromes (PAIS) — a large, underserved category affecting an estimated 21 million people in the U.S. with no widely adopted objective diagnostic test.Virax's lead product, ViraxImmune™, is designed to move beyond static blood markers and deliver objective immune dysfunction profiling for conditions including Long COVID, ME/CFS, and post-treatment Lyme disease which collectively represent an economic burden exceeding $25 billion annually in the U.S.James walks investors through the company's planned U.S. market entry via the laboratory-developed test (LDT) pathway, its clinical validation milestones underway in 2026, a near-term data readout, and the path toward a targeted 2027 commercial launch — all supported by a strengthened balance sheet of approximately $6.4M in cash and no debt.👉 Virax Biolabs is a client of RedChip. To learn more about VRAX and sign up for news alerts, visit: https://www.redchip.com/stocks/VRAX#VRAX #ViraxBiolabs #LongCOVID #MECFS #DiagnosticsStocks #Nasdaq #SmallCapStocks #MicroCapStocks #Biotech #MedTech #InvestorEducation #StockInterviews #PostAcuteInfection #HealthcareStocks

In our investor-focused interview, Jeremy Schwartz, Global CIO of WisdomTree (NYSE: WT), breaks down how the firm grew from 20 funds to a $165B global asset manager delivering 50% annual earnings growth — and why he believes WT trades at a significant discount to its true growth profile.Jeremy covers WisdomTree's framework for identifying durable mega-trends, the $5B European defense ETF launched just 13 months ago, its newly launched U.S. minerals ETF, and a $40B commodities business built for today's geopolitical environment. With margins expanding from 20% to the low 40s and a CEO-backed buyback program accelerating, the case for multiple expansion is building.👉 To learn more about WisdomTree and sign up for news alerts, visit: https://www.redchip.com/stocks/WT#WT #WisdomTree #ETF #AssetManagement #CriticalMinerals #RareEarths #GeopoliticsInvesting #DefenseETF #Commodities #SmallCapStocks #StockInterviews #InvestorEducation #ETFInvesting #NYSE

In our exclusive interview, John Passalacqua, CEO & Director of First Phosphate ($FRSPF | CSE: PHOS), discusses the seismic $94 million all-cash acquisition by Avenir Minerals (Agnico Mines subsidiary) and explains what it signals for the LFP battery supply chain and for First Phosphate.Key topics from the interview include:• Agnico Eagle's $94M all-cash acquisition of Fox River Resources — and what it signals about the strategic value of igneous phosphate.• Why only 2 independent igneous phosphate companies remain in North America, and how First Phosphate stands out with the larger market cap and deposit closest to port.• First Phosphate's exclusive focus on igneous anorthosite phosphate for LFP batteries — and why they avoid sedimentary deposits and carbonatites entirely.• Phosphate comprises ~60% of LFP cathode mass vs. lithium's ~4% — and why Benchmark Minerals ranks it the #2 most critical mineral for the energy transition.• First Phosphate's mine-to-market strategy spanning phosphate rock through purified phosphoric acid, cathode active material, and LFP battery cells.• Project scale: ~255M tonne resource, ~900K tonnes/year concentrate, CAD $2.1B NPV, ~37% IRR, ~3-year payback.👉 First Phosphate is a client of RedChip. Visit https://www.FRSPFinfo.com to learn more and sign up for news alerts.#FRSPF #PHOS #FirstPhosphate #LFPBatteries #BatteryMaterials #CriticalMinerals #EnergyStorage #EVStocks #SmallCapStocks #MicroCapStocks #InvestorInterview

Anixa Biosciences (Nasdaq: ANIX) is advancing a clinical-stage oncology pipeline focused on cancer vaccines and CAR-T therapy, led by its breast cancer vaccine program developed with Cleveland Clinic and supported by U.S. Department of Defense funding.In our exclusive interview, Dr. Amit Kumar, Chairman & CEO of Anixa Biosciences, discusses the company’s breast cancer vaccine targeting alpha-lactalbumin, its completed Phase 1 study, the path toward Phase 2, and the long-term vision of potentially preventing breast cancer before it starts. Dr. Kumar also highlights Anixa’s ovarian cancer CAR-T program, where early clinical data has shown extended survival in certain heavily pretreated patients.Why investors are watching ANIX:• Breast cancer vaccine Phase 1 completed with no major safety concerns reported• 74% protocol-specified immune response reported in Anixa’s investor deck• Phase 2 breast cancer vaccine enrollment listed as an upcoming milestone• Ovarian cancer CAR-T program provides a second clinical-stage opportunity• $14M in cash and short-term investments, no debt, and a clean capital table as of January 31, 2026• Partnerships include Cleveland Clinic, The Wistar Institute, and U.S. Department of Defense supportLearn more about Anixa Biosciences: https://www.redchip.com/stocks/ANIX#ANIX #AnixaBiosciences #BiotechStocks #CancerVaccine #BreastCancer #CART #Oncology #SmallCapStocks #NASDAQ #InvestorInterview #RedChip

In our exclusive interview, Brandon Robinson, Co-Founder, CEO, and Director of New Horizon Aircraft (Nasdaq: HOVR) breaks down why Horizon is taking a different path in advanced air mobility and why investors are starting to pay attention.Horizon’s Cavorite X7 is designed to combine vertical takeoff capability with the speed, range, and economics of a conventional aircraft. The company is targeting performance of about 250 mph, 500-mile range, and up to 1,500 lbs of payload, with operating costs estimated at about $0.97 per seat mile versus roughly $4 to $6 for comparable helicopters. The company has also completed large-scale prototype testing, including vertical takeoff, transition, and forward flight, with a full-scale aircraft currently under construction.For investors, the story is about more than innovation. Horizon is targeting a large installed base of roughly 70,000 helicopters globally, pursuing a capital-efficient OEM model, and positioning itself in high-value mission-critical markets where infrastructure-light aircraft can solve real operational problems. 👉 New Horizon Aircraft is a client of RedChip. Visit https://www.HOVRinfo.com to learn more and sign up for news alerts.#HOVR #HorizonAircraft #eVTOL #AviationStocks #SmallCapStocks #GrowthStocks #Investing #Nasdaq #AirMobility #Aerospace

In our exclusive interview, John Passalacqua, CEO & Director of First Phosphate, explains why First Phosphate ($FRSPF | CSE: PHOS) is positioning itself as a critical North American supplier to the fast-growing LFP battery market.Key topics from the interview include:• A $16.7 million non-dilutive contribution from the Government of Canada, helping advance feasibility work and key process validation without additional equity dilution, according to management.• Why igneous phosphate matters for battery applications, including its high purity and potential efficiency in conversion to battery-grade phosphate for LFP batteries.• First Phosphate’s vertically integrated strategy, spanning phosphate rock, concentrate, purified phosphoric acid, iron phosphate precursor, cathode active material, and LFP battery cells, as shown in the value chain graphic on page 2 of the fact sheet.• Commercial traction, including management commentary on a definitive bankable offtake agreement and prepayment from a European partner.• Scale potential supported by an advanced resource of approximately 255 million tonnes and a Preliminary Economic Assessment highlighting ~900,000 tonnes per year of phosphate concentrate, ~CAD $2.1B NPV, ~37% IRR, and ~3-year payback.• Why management believes phosphate is the overlooked input in LFP batteries, with phosphate representing a major share of cathode mass.👉 First Phosphate is a client of RedChip. Visit https://www.FRSPFinfo.com to learn more and sign up for news alerts.#FRSPF #PHOS #FirstPhosphate #LFPBatteries #BatteryMaterials #CriticalMinerals #EnergyStorage #EVStocks #SmallCapStocks #MicroCapStocks #InvestorInterview

This week's episode of Small Stocks Big Money features exclusive interviews with senior executives from Enlivex Therapeutics Ltd. (NASDAQ: ENLV) & Off The Hook Inc. (NYSE American: OTH)Explore the latest insights and updates in the world of small-cap stocks.Visit RedChip.com to learn more.